Zydus and Glenmark Top Pharma Growth Charts in August

us Lifesciences and Glenmark Pharmaceuticals delivered the strongest value growth among companies tracked by Nomura in August 2026, according to the brokerage’s September 8 note. The broader India pharmaceuticals market (IPM) expanded 10.7% year-on-year, supported by price hikes of 6.1%, new product launches contributing 3.5%, and modest volume growth of 1.1%. Nomura noted that after subdued years in 2024 and 2025, IPM growth has recovered to double-digit levels in 2026, helped by a low base, rising contribution from GLP-1 therapies, stronger demand in chronic segments such as cardiac and oncology, and solid traction in vitamins, minerals and nutrients (VMNs) as well as gynaecology. On a moving annual total (MAT) basis through August, Glenmark led with 14.9% year-on-year growth, followed closely by Torrent Pharma at 14.8% and Zydus at 14.1%.